Two global pharma companies withdraw from the UK’s Voluntary Scheme for Branded Medicines Pricing ...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreOur client needed a rapid pricing and market access (P&MA) assessment across the US and EU5 in sever...
Read moreOur client wanted to develop a training programme to help their employees learn about the value of M...
Read moreDevelopment of an EU pricing and market access e-Learning training resource to provide awareness of ...
Read moreDevelopment and delivery of training covering the fundamental principles of RWE, including defining ...
Read moreThe company found themselves facing competitive tenders for the first time in this disease space - t...
Read moreOur client was seeking NICE approval for their ultra-orphan drug in an indication that was not well ...
Read moreIdentification of current cost of oncology care treatment options.
Read moreDevelopment of local market access plans that could be used by EU affiliates, who had not previously...
Read more